Apr 27, 2021
[1 min Read]
Teladoc is a telemedicince and virtual healthcare company. In 2020 and due to the pandemic, the company grew rapidly and its revenue grew 98% year over year to $1.093 billion. Also, its EBITDA increased four-fold to $126.8 million and the stock price grew by 139%.
Since March 20201, however, there has been an almost 40% decrease in Teladoc's stock price, as investors expect the usage of the platform to fall now that the end of the pandemic is in sight. With that being said, I believe that these fears are overexagerated. Customers' habits and lifestyle have evolved due to the pandemic, and the Teladoc platform will continue to be popular as it is a cheaper and much more efficient alternative. In fact, research shows that 76% of Americans would now want to seek care over the internet, compared to only 11% before the pandemic. Also, Teladoc has made some promising acquisitions. Most notably, it acquired Livongo Health in 2020, a chronic disease treatment platform that has already grown in popularity.
I believe that Teladoc stocks are great invetments right now. With a diverse array of virtual health services and a growing subscriber base, the company is projecting a 25.7% two-year forward growth rate for its revenues, which could end up being a conservative estimate. Also, due to the 40% decrease of the stock price, the multiples have gotten a lot cheaper and are now even lower than they were in March 2020. There is also the opportunity for Teladoc to expand further internartionally to grow its customer base. Thus, I believe that the stock could bounce back and reach new all-time highs in the near future.